VIVUS,INC. (NASDAQ:VVUS) Files An 8-K Other Events
Item 8.01. Other Events
On January14, 2019, VIVUS,Inc. issued a press release titled “Data Supporting the Cardiovascular Safety of VIVUS’ Qsymia®Published in The Journal of Clinical Endocrinology& Metabolism.” A copy of the press release is attached hereto as Exhibit99.1 and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits
VIVUS INC Exhibit
EX-99.1 2 a19-2761_1ex99d1.htm EX-99.1 Exhibit 99.1 Data Supporting the Cardiovascular Safety of VIVUS Qsymia® Published in The Journal of Clinical Endocrinology & Metabolism -Study finds no increase in risk for major adverse cardiovascular events for individuals currently using phentermine in combination with topiramate; study adds to robust data supporting the safety and efficacy of Qsymia- CAMPBELL,…
To view the full exhibit click
About VIVUS,INC. (NASDAQ:VVUS)
VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company has completed the Phase II studies of Qsymia for the indication of Obstructive Sleep Apnea (OSA) and diabetes. Its Qsymia is available in over 40,000 certified retail pharmacies across the country. Its STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. The United States Food and Drug Association approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.